Azacitidine in the management of patients with myelodysplastic syndromes.
about
Epigenetic regulation of endothelial-cell-mediated vascular repairEpigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries.DNA methylation profiles in cancer diagnosis and therapeutics.Emerging biological therapies for the treatment of myelodysplastic syndromes.Rewiring the solid tumor epigenome for cancer therapy.tp53-dependent G2 arrest mediator candidate gene, Reprimo, is down-regulated by promoter hypermethylation in pediatric acute myeloid leukemia.A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece.Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.Epigenetics: The Future Direction in Systemic Sclerosis.Necrotizing fasciitis in two patients with myelodysplastic syndrome treated with azacitidine.DNA methylation of hepatic iron sensing genes and the regulation of hepcidin expression.
P2860
Q28085420-9F157800-372B-4877-9967-7C021D1AEE5AQ38332497-E6F47BC7-EDE9-42AE-8C53-88A70A23E757Q38650593-950D6485-34BA-4887-9551-8AFC34FC082EQ38834981-EEEEB918-5AE6-413F-909D-8FB2EEEF9FE6Q38895216-136C6604-8916-446C-9CF5-2DB24AE3AAC0Q38915689-1701C999-39AF-44A1-8001-7F6B5ABAA205Q38999351-02AA0EDB-4C56-4DAB-AA64-96C62E487119Q44866521-CEE31DE8-F5E0-43EE-B536-BB7E76BA92D1Q47939031-1269020F-36BC-444D-ADE7-3395A48E5074Q51725692-33F09C2A-D4BB-4F9A-88EB-2FB309A5E227Q54943445-1CC8483B-D5D9-443E-875A-104A57B403D3
P2860
Azacitidine in the management of patients with myelodysplastic syndromes.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Azacitidine in the management of patients with myelodysplastic syndromes.
@ast
Azacitidine in the management of patients with myelodysplastic syndromes.
@en
type
label
Azacitidine in the management of patients with myelodysplastic syndromes.
@ast
Azacitidine in the management of patients with myelodysplastic syndromes.
@en
prefLabel
Azacitidine in the management of patients with myelodysplastic syndromes.
@ast
Azacitidine in the management of patients with myelodysplastic syndromes.
@en
P2093
P2860
P356
P1476
Azacitidine in the management of patients with myelodysplastic syndromes.
@en
P2093
Cyrus Khan
James M Rossetti
John Lister
Neeta Pathe
Salman Fazal
P2860
P304
P356
10.1177/2040620712464882
P577
2012-12-01T00:00:00Z